VPS53 Antibody

What is VPS53 and what cellular functions does it mediate?

VPS53 (vacuolar protein sorting 53 homolog) is a critical component of the Golgi-associated retrograde protein (GARP) complex, also called VFT (VPS fifty-three) complex. This complex consists of VPS51, VPS52, VPS53, and VPS54 subunits and functions primarily in retrograde traffic from endosomes to the trans-Golgi network . The GARP complex mediates this function through interactions with RAB proteins and SNARE proteins, which are essential for membrane fusion events . Recent research has demonstrated that VPS53 plays a crucial role in cellular sphingolipid homeostasis, as VPS53-deficient cells show significant disruptions in sphingolipid metabolism, including an eightfold increase in total long-chain bases and approximately twofold reduction in complex sphingolipid M(IP)2C .

What types of VPS53 antibodies are commercially available for research applications?

Researchers have access to both monoclonal and polyclonal antibodies targeting VPS53. Monoclonal options include mouse-derived antibodies such as 67610-1-Ig, which targets VPS53 in WB, IHC, IF/ICC, and ELISA applications with reactivity against human, mouse, and rat samples . Polyclonal alternatives include rabbit-derived antibodies like PACO17431, validated for ELISA, WB, and IHC applications with reactivity against human and mouse samples . The selection between monoclonal and polyclonal antibodies should be based on the specific experimental requirements, with monoclonal antibodies offering higher specificity for particular epitopes, while polyclonal antibodies provide broader epitope recognition and potentially stronger signals through multiple binding sites.

What sample types and species have been validated for VPS53 antibody applications?

VPS53 antibodies have been validated across multiple sample types and species. The monoclonal antibody 67610-1-Ig has demonstrated positive Western blot detection in a wide range of cell lines including U2OS, HeLa, NIH/3T3, HEK-293, HepG2, Jurkat, K-562, HSC-T6, LNCaP, and 4T1 cells . For immunohistochemistry, positive detection has been confirmed in human liver tissue and rat brain tissue, with suggested antigen retrieval using TE buffer pH 9.0 or citrate buffer pH 6.0 . Immunofluorescence/ICC applications have been validated in HEK-293 cells . The polyclonal antibody PACO17431 shows reactivity with human and mouse samples . This cross-species reactivity makes these antibodies valuable tools for comparative studies across different model organisms.

How should researchers optimize antigen retrieval for VPS53 immunohistochemistry?

For optimal antigen retrieval in VPS53 immunohistochemistry experiments, researchers should first attempt TE buffer at pH 9.0, which is the primary recommended method for antibodies like 67610-1-Ig . If results are suboptimal, an alternative approach using citrate buffer at pH 6.0 may yield better results . The effectiveness of antigen retrieval can vary depending on tissue fixation methods, tissue type, and the duration of fixation. For formalin-fixed paraffin-embedded (FFPE) samples, heat-induced epitope retrieval is typically necessary, while frozen sections may require less intensive retrieval methods. Researchers should systematically compare both buffer systems at various incubation times (typically 10-20 minutes) and temperatures to determine the optimal conditions for their specific tissue samples, as VPS53 detection sensitivity can vary significantly between different tissue types.

What are the optimal storage conditions for preserving VPS53 antibody activity?

To maintain optimal VPS53 antibody activity, storage at -20°C is recommended for both monoclonal and polyclonal antibodies . Monoclonal antibodies like 67610-1-Ig are typically stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, and remain stable for one year after shipment . For the 20μl size, the formulation contains 0.1% BSA . Polyclonal antibodies such as PACO17431 are stored in pH 7.4 PBS with 0.05% NaN3 and 40% glycerol . Both antibody types should be kept in aliquots to minimize freeze-thaw cycles, although the high glycerol content (40-50%) makes aliquoting unnecessary for -20°C storage in some cases . Upon thawing for use, antibodies should be maintained at 4°C and used within a week to prevent degradation and loss of activity. Extended storage at room temperature or 4°C is not recommended as it can lead to significant reduction in antibody performance.

How can researchers troubleshoot non-specific binding in Western blot applications using VPS53 antibodies?

When encountering non-specific binding in Western blot applications with VPS53 antibodies, researchers should implement a systematic troubleshooting approach. First, optimize blocking conditions by testing different blocking agents (5% non-fat milk, 5% BSA, or commercial blocking reagents) and increasing blocking time to reduce background. Second, adjust antibody dilution ratios—for monoclonal VPS53 antibodies like 67610-1-Ig, try higher dilutions within the recommended 1:2000-1:10000 range . Third, incorporate additional washing steps with higher stringency wash buffers (increasing Tween-20 concentration to 0.1-0.3%). Fourth, pre-absorb the antibody with the blocking agent before incubation with the membrane. Fifth, for persistent non-specific binding, consider using gradient SDS-PAGE gels to better resolve the 94 kDa VPS53 protein from potentially cross-reactive proteins. Since VPS53 is part of a complex with other VPS proteins, some antibodies may cross-react with structurally similar components of the GARP complex, so validating specificity using knockout/knockdown samples is highly recommended.

What controls should be included when using VPS53 antibodies for functional studies?

Rigorous experimental design for VPS53 antibody-based studies should include multiple controls. First, a positive control using cell lines with confirmed VPS53 expression (such as U2OS, HeLa, HEK-293, or HepG2 cells) should be included . Second, a negative control using VPS53 knockout or knockdown samples is essential to confirm antibody specificity. Third, for immunofluorescence studies, include a secondary antibody-only control to assess background fluorescence. Fourth, when studying GARP complex functionality, consider using mutant VPS53 constructs (such as VPS53 Q695R, which has been shown to cause defects similar to, though less severe than, VPS53 deletion) . Fifth, when examining sphingolipid homeostasis disruptions in VPS53-deficient models, include myriocin treatment controls, as this has been shown to partially rescue some phenotypes in vps53Δ cells . Finally, for studies involving sphingolipid trafficking, comparative analysis using both NBD-sphingosine and FM4-64 markers will help distinguish normal from disrupted trafficking patterns .

How can VPS53 antibodies be used to investigate GARP complex assembly and trafficking defects?

VPS53 antibodies can be powerfully employed to investigate GARP complex assembly and trafficking defects through multiple methodological approaches. For co-immunoprecipitation experiments, researchers can use VPS53 antibodies to pull down the entire GARP complex and analyze interactions with other components (VPS51, VPS52, and VPS54) under various cellular conditions or in disease models. In immunofluorescence studies, dual staining with VPS53 antibodies and markers for different cellular compartments (including Golgi markers like GM130, TGN markers like TGN46, and endosomal markers like EEA1 or Rab proteins) can reveal alterations in localization patterns indicative of trafficking defects. Advanced approaches include using VPS53 antibodies in proximity ligation assays (PLA) to detect in situ protein interactions within the GARP complex with nanometer resolution. For quantitative assessment of trafficking defects, researchers should combine VPS53 immunostaining with trafficking assays using NBD-sphingosine, which normally localizes to foci representing compartments of the endosomal/secretory pathway in wild-type cells but co-localizes with FM4-64 in fragmented vacuoles in VPS53-deficient cells .

What insights can be gained from comparing phenotypes across different VPS53 mutation models using specific antibodies?

Comparative analysis of different VPS53 mutation models using specific antibodies can yield important insights into structure-function relationships and disease mechanisms. Studies comparing the Q695R mutation to complete VPS53 deletion have revealed that this point mutation leads to defects similar to, though less severe than, those seen in complete knockouts . Researchers should employ domain-specific VPS53 antibodies to determine how different mutations affect protein folding, complex assembly, and subcellular localization. For instance, antibodies targeting the C-terminal fragment (residues 554-822) can be particularly informative since crystallographic studies have focused on this region (residues 564-730 and 742-779) . When analyzing phenotypes, researchers should assess multiple parameters including: sphingolipid metabolism (measuring long-chain bases like DHS and PHS, which increase approximately tenfold and threefold respectively in vps53Δ cells); vacuolar morphology (vps53Δ cells typically show highly fragmented vacuoles); and sphingolipid trafficking (using fluorescent sphingolipid analogs) . Cross-species comparison using antibodies reactive with human, mouse, and rat VPS53 can further illuminate evolutionarily conserved functions versus species-specific roles.

How can VPS53 antibodies be leveraged to study the relationship between GARP complex dysfunction and sphingolipid homeostasis?

To investigate the relationship between GARP complex dysfunction and sphingolipid homeostasis, researchers can implement a multi-method approach using VPS53 antibodies. Begin with co-localization studies using VPS53 antibodies alongside fluorescent sphingolipid probes like NBD-sphingosine to track trafficking patterns in normal versus GARP-deficient cells. In wild-type cells, NBD-sphingosine localizes to discrete foci in the endosomal/secretory pathway, whereas in vps53Δ cells, it aberrantly co-localizes with FM4-64 in fragmented vacuoles . For mechanistic studies, researchers should combine VPS53 immunoprecipitation with lipidomic analysis to identify sphingolipid species directly associated with the GARP complex. Time-course experiments using VPS53 knockdown or inhibition followed by mass spectrometry-based sphingolipid profiling can reveal the temporal relationship between GARP dysfunction and lipid abnormalities. Additionally, researchers should examine the rescue effect of sphingolipid synthesis inhibitors like myriocin, which partially normalizes vacuolar morphology in vps53Δ cells . For comprehensive analysis, combine immunofluorescence microscopy of VPS53 with measurements of dihydrosphingosine (DHS; increased ~tenfold in vps53Δ), phytosphingosine (PHS; increased ~threefold), and complex sphingolipid M(IP)2C (reduced ~twofold) .

What techniques can be used to assess VPS53 antibody specificity in complex tissue samples?

Ensuring VPS53 antibody specificity in complex tissue samples requires rigorous validation through multiple complementary techniques. First, researchers should perform pre-absorption tests by incubating the antibody with excess purified VPS53 protein or immunizing peptide before application to tissue samples—a specific antibody will show significantly reduced or eliminated staining. Second, implement comparative staining with multiple VPS53 antibodies targeting different epitopes; concordant staining patterns increase confidence in specificity. Third, validate antibody specificity using genetic models with VPS53 knockout or knockdown in targeted tissues, which should show corresponding reduction or absence of signal. Fourth, for human tissue samples where genetic manipulation is not possible, utilize RNA-scope or in situ hybridization to correlate protein detection with mRNA expression patterns. Fifth, employ western blotting of tissue lysates to confirm detection of a single band at the expected molecular weight (94 kDa for VPS53) . Finally, for particularly complex tissues like brain samples (where VPS53 antibodies have been validated for IHC in rat brain tissue) , compare staining patterns across multiple fixation and antigen retrieval protocols to distinguish true signal from artifacts.

How can researchers optimize VPS53 antibody protocols for studying neurodegenerative disease models?

When studying neurodegenerative disease models with VPS53 antibodies, researchers should implement several optimization strategies. First, for brain tissue immunohistochemistry, modify standard antigen retrieval by extending incubation times with TE buffer (pH 9.0) to 25-30 minutes to overcome the increased cross-linking found in neural tissues . Second, reduce background autofluorescence in immunofluorescence studies by incorporating additional treatment steps with sodium borohydride (1mg/ml in PBS) for 30 minutes before blocking. Third, when studying neuronal cultures, adjust permeabilization conditions using lower detergent concentrations (0.1% Triton X-100 for 10 minutes) to preserve delicate neuronal structures while allowing antibody access. Fourth, for co-localization studies in neurons, combine VPS53 immunostaining with markers for neuronal compartments including synaptic vesicles (synaptophysin), endosomes (Rab5, Rab7), and autophagosomes (LC3) to assess potential trafficking defects. Fifth, when analyzing brain samples from neurodegenerative disease models, implement quantitative analysis of VPS53 staining intensity in specific neuroanatomical regions affected by the disease compared to control regions. Finally, consider using proximity ligation assays (PLA) to detect potential disease-specific alterations in VPS53 interactions with other GARP components or trafficking machinery in neurons.

What considerations are important when using VPS53 antibodies in live cell imaging experiments?

Live cell imaging with VPS53 antibodies presents unique challenges requiring specific methodological adaptations. First, researchers must use antibody fragments (Fab fragments) rather than whole IgG molecules to improve cellular penetration and reduce interference with protein function. Second, careful selection of fluorophore conjugates is essential—choose small, bright fluorophores with good photostability like Alexa Fluor 488 or 647 rather than larger fluorescent proteins that might disrupt protein function. Third, implement gentle permeabilization techniques using streptolysin O (15-25 U/ml) or digitonin (10-20 μg/ml) rather than traditional detergents to maintain cell viability while allowing antibody entry. Fourth, optimize antibody concentration to the minimum effective dose (typically starting at 1:1000 dilution of stock and titrating as needed) to minimize potential disruption of normal cellular processes. Fifth, include appropriate controls including non-binding isotype-matched antibodies labeled with the same fluorophore to control for non-specific effects of antibody introduction. Finally, validate all live-cell observations with complementary fixed-cell techniques, as some apparent trafficking abnormalities may result from the introduction of antibodies rather than representing normal VPS53 dynamics.

How can researchers combine VPS53 antibody-based techniques with genetic approaches to study GARP complex function?

An integrated approach combining VPS53 antibody techniques with genetic methods provides powerful insights into GARP complex function. First, implement CRISPR/Cas9-mediated tagging of endogenous VPS53 with small epitope tags (FLAG, HA, or V5) to enable comparison between endogenous protein detection using VPS53-specific antibodies and epitope tag antibodies, providing validation of staining patterns. Second, create domain-specific mutations in VPS53 (particularly in the C-terminal region where structural data is available, residues 564-822) and use VPS53 antibodies to assess effects on protein stability, localization, and complex formation . Third, in yeast models, combine VPS53 mutations with CPY secretion assays to correlate structural alterations with functional defects in trafficking . Fourth, implement rescue experiments in VPS53-knockout backgrounds with various mutant constructs and use immunofluorescence with VPS53 antibodies to assess restoration of proper localization patterns. Fifth, combine antibody-based proximity labeling techniques (BioID or APEX) with genetic manipulation of VPS53 to identify interaction partners altered by specific mutations. Finally, implement conditional knockout models (using Cre-lox or similar systems) with time-course sampling and immunostaining to determine the temporal sequence of cellular changes following VPS53 depletion.

What methodological approaches best combine VPS53 antibody detection with lipidomic analysis in studying sphingolipid trafficking defects?

To effectively combine VPS53 antibody detection with lipidomic analysis for studying sphingolipid trafficking defects, researchers should implement an integrated workflow. First, perform subcellular fractionation followed by immunoisolation using VPS53 antibodies to purify GARP-containing membrane compartments, then analyze the lipid composition of these fractions using liquid chromatography-mass spectrometry (LC-MS). Second, employ pulse-chase experiments with fluorescent or isotope-labeled sphingolipid precursors, followed by VPS53 immunostaining or immunoisolation to track the movement of newly synthesized sphingolipids through GARP-positive compartments. Third, implement correlative light and electron microscopy (CLEM) combining VPS53 immunofluorescence with electron microscopy and lipid-specific staining techniques to visualize both protein localization and lipid distribution at ultrastructural resolution. Fourth, use VPS53 antibodies for immunoprecipitation followed by activity assays of associated lipid-modifying enzymes to assess whether GARP dysfunction directly affects enzymatic activity in the sphingolipid metabolic pathway. Fifth, develop quantitative image analysis workflows that combine VPS53 immunofluorescence with fluorescent sphingolipid probes (NBD-sphingosine) and organelle markers (FM4-64) to measure colocalization coefficients and trafficking kinetics . Finally, compare results between normal conditions and after pharmacological intervention with compounds like myriocin, which partially rescues vacuolar morphology defects in VPS53-deficient cells .

How might new developments in super-resolution microscopy enhance VPS53 antibody applications in trafficking research?

Emerging super-resolution microscopy techniques offer transformative potential for VPS53 antibody applications in trafficking research. First, Stimulated Emission Depletion (STED) microscopy can achieve resolution below 50nm, enabling researchers to precisely map VPS53 localization within the Golgi and endosomal compartments with unprecedented detail, clarifying the spatial organization of the GARP complex. Second, Single-Molecule Localization Microscopy (SMLM) techniques like PALM and STORM can track individual VPS53 molecules, revealing dynamic clustering and dispersal during trafficking events and potentially identifying discrete GARP complex assembly sites. Third, Expansion Microscopy physically enlarges specimens, allowing conventional confocal microscopes to achieve super-resolution imaging of VPS53 in relation to other trafficking machinery at nanoscale precision. Fourth, lattice light-sheet microscopy combined with adaptive optics enables long-term 3D imaging of living cells with minimal phototoxicity, ideal for tracking VPS53-positive vesicle dynamics during trafficking events. Fifth, correlative light-electron microscopy (CLEM) with super-resolution fluorescence can link nanoscale VPS53 localization to ultrastructural features. For optimal implementation, researchers should use small-epitope tagged VPS53 constructs or directly conjugated primary antibodies to minimize the displacement error inherent in traditional primary-secondary antibody detection systems, which can compromise the precision advantages of super-resolution techniques.

What potential exists for using VPS53 antibodies in developing therapeutic approaches for sphingolipid-related disorders?

VPS53 antibodies hold significant potential for developing therapeutic approaches for sphingolipid-related disorders through multiple translational pathways. First, these antibodies can serve as critical tools for high-throughput screening assays to identify compounds that normalize GARP complex function or downstream sphingolipid metabolism in disease models. Second, researchers can develop cell-penetrating antibody derivatives (such as single-chain variable fragments or nanobodies) targeting specific VPS53 domains to modulate GARP complex function in vivo. Third, VPS53 antibodies can be used to identify and validate biomarkers of sphingolipid dysregulation in patient samples, enabling earlier diagnosis and treatment monitoring for conditions like lysosomal storage disorders. Fourth, for genetic disorders involving VPS53 mutations (such as those causing the Q695R variant), antibody-based approaches can assess whether specific compounds can stabilize mutant protein and restore function . Fifth, therapeutic strategies combining VPS53 stabilization with sphingolipid pathway modulation (such as with myriocin derivatives, which have shown partial rescue effects in model systems) can be evaluated using antibody-based assays to monitor cellular responses . Finally, VPS53 antibodies can help evaluate the efficacy of gene therapy approaches by monitoring the expression, localization, and function of wild-type VPS53 delivered to cells with defective endogenous protein.

How can researchers optimize multiplexed detection systems incorporating VPS53 antibodies for studying complex trafficking networks?

Optimizing multiplexed detection systems incorporating VPS53 antibodies requires strategic methodological approaches to overcome technical limitations and maximize informational output. First, implement sequential immunostaining protocols using tyramide signal amplification (TSA), which allows multiple primary antibodies from the same species to be used sequentially by eliminating the first antibody through microwave treatment before applying the next antibody. Second, utilize antibody panels with complementary host species (mouse monoclonal VPS53 antibodies combined with rabbit polyclonal antibodies against other GARP components or trafficking markers) to enable simultaneous detection . Third, incorporate metal-conjugated antibodies for mass cytometry (CyTOF) or Imaging Mass Cytometry, enabling simultaneous detection of 30+ markers including VPS53 and related trafficking proteins without spectral overlap limitations. Fourth, employ cyclic immunofluorescence (CycIF) or iterative indirect immunofluorescence imaging (4i), which allow sequential imaging rounds with fluorophore inactivation between cycles, potentially visualizing dozens of targets in the same sample. Fifth, for tissue microarray analysis, implement quantitative multispectral imaging systems to accurately separate VPS53 signals from tissue autofluorescence and other markers. Finally, develop computational image analysis pipelines using machine learning algorithms to extract pathway-level information from multiplexed datasets, enabling quantitative assessment of how VPS53 dysfunction impacts multiple trafficking pathways simultaneously.

What considerations should researchers address when developing new VPS53 antibodies for specialized research applications?

When developing new VPS53 antibodies for specialized research applications, researchers should address several critical considerations. First, conduct comprehensive epitope mapping of existing antibodies to identify underrepresented regions of VPS53, particularly focusing on functional domains like the C-terminal fragment (residues 554-822) where structural data is available and mutations are known to cause functional defects . Second, design immunization strategies using recombinant protein fragments rather than synthetic peptides when targeting conformational epitopes, especially for antibodies intended for immunoprecipitation or functional blocking studies. Third, incorporate extensive cross-reactivity testing across species (human, mouse, rat) and between related VPS family proteins to ensure specificity while maximizing cross-species utility . Fourth, validate new antibodies using multiple techniques including western blotting, immunoprecipitation, immunofluorescence, and flow cytometry with both overexpression and knockout controls. Fifth, for antibodies intended for super-resolution microscopy, optimize conjugation strategies for direct fluorophore labeling at defined antibody:dye ratios to maximize signal while maintaining affinity. Sixth, for antibodies targeting specific VPS53 isoforms or post-translationally modified variants, implement rigorous validation with mass spectrometry to confirm precise epitope recognition. Finally, for antibodies intended for therapeutic development, address manufacturing considerations early including stability testing, scale-up potential, and humanization strategies if derived from mouse or rabbit hosts.